Oncimmune Regulatory News (ONC)

Oncimmune Holdings plc

("Oncimmune" or the "Company")

Appointment of Dr. Cheung To as Non-Executive Director

Nottingham, UK - 28 September 2018: Oncimmune Holdings plc (AIM: ONC.L), a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® liquid biopsy platform technology, today announces the appointment of Dr. Cheung To as a Non-Executive Director with immediate effect.

Dr. Cheung To joins following Oncimmune's licence agreement with Genostics Company Limited ("Genostics"), announced in January 2018, when it was agreed that a representative from Genostics would be appointed to Oncimmune's Board.

Dr. Cheung To is an entrepreneur with over 25 years' of extensive experience in biotechnology research and instinctive knowledge of the development of the world's, and China's, biotechnology markets. He co-founded and is Chairman of Gene Group Co. Ltd., a group that now includes several major companies including: Gene Co. Ltd., one of the largest professional service and distribution provider for the medical, life science, pharmaceutical and biotech research sectors in China; Ecotek Co. Ltd., a professional services company to the agricultural and environmental research sectors in China; Genetech (Shanghai) Co. Ltd., a business focused on R&D, manufacturing, marketing & distribution of molecular and cellular diagnostic products in the fields of pathology, oncology, heamatology and molecular genetics; Ebiotrade.com, a Biotech portal and e-commerce provider; and Baygene Co. Ltd., a company focused on R&D, manufacturing and distribution of life-science research products.

Dr. Cheung To obtained his Ph.D from the University of Hong Kong, Medical Faculty, Dept. of Biochemistry in 1996, and he was awarded one of the experts in the prestige China's National "Recruitment Program of Global Experts" (known as "the Thousand Talents Program") in 2010, in recognition of his contribution towards the industries and society.

Meinhard Schmidt, Non-Executive Chairman of Oncimmune, commented: "I am delighted to welcome Dr. Cheung To to the Board. We have already established a strong working relationship while securing our framework and distribution agreement in China, and this has continued as we progress with the preparation for sales to commence. Dr. Cheung To's track record speaks for itself and I look forward to drawing on his experience in developing and commercialising devices in China, a significant market for Oncimmune."

Dr. Cheung To, Non-Executive Director of Oncimmune, commented: "I am excited by Oncimmune's EarlyCDT® platform technology and its potential to significantly improve outcomes for cancer patients through early detection of disease and by enhancing the treatment pathway. I look forward to continuing to work with the Oncimmune team to maximise its potential more widely in China."

The following information is disclosed pursuant to Schedule Two, paragraph (g) of the AIM Rules for Companies:

- Full name and age: To Cheung (55)

- Current Directorships:

o Gene Company Ltd

o Gene Group Holdings Ltd

o Gene International Group Inc.

o Gene Investment Holdings Inc.

o Gene Biotechnology International Trade (Shanghai) Co Ltd

o Gene Tech Investment Holdings Inc.

o Gene Tech (Hong Kong) Company Ltd.

o Genetech Biotechnology (shanghai) Co. Ltd

o GeneTech (Shanghai) Company Ltd

o Baygene Company Limited

o GeneTech (Macau) Company Limited

o Teanologies company Limited

o eBiotrade.com Limited

o Gene Scientific Company Limited

o Natural Herbs Technology Co. Limited

o Bioservices Company Limited

o Genostics Company Limited

o Global Gene Investment Inc.

o Hong Kong CH Gene Co Ltd

o Winchester Development Co. Limited

o Beijing Baygene Biotech Company Limited

o Shanghai GeneTech Target medical Laboratory Company Limited

o Guangzhou Ebiotrade.com Biotechnology Company Ltd.

o Shanghai Baygene Biotech Company Limited

- Past Directorships (within the previous 5 years):

- None

No further information in connection with his appointment is required to be disclosed under Schedule Two, paragraph (g) of the Aim Rules for Companies.

For further information:

Oncimmune Holdings plc

Adam Hill, Chief Executive Officer

contact@oncimmune.co.uk

Zeus Capital Limited (Nominated Adviser and Joint Broker)

Andrew Jones

+44 (0)20 3829 5000

Bryan, Garnier & Co Limited (Joint Broker)

Phil Walker, Dominic Wilson

+44 (0)20 7332 2500

Berenberg (Joint Broker)

Toby Flaux, Charlotte Sutcliffe

+44 (0)20 3207 7800

Media enquiries:

Consilium Strategic Communications

Chris Gardner, Matthew Neal, Lindsey Neville

Oncimmune@consilium-comms.com

+44 (0)20 3709 5708

About Oncimmune

Oncimmune is a leading early cancer detection company developing and commercialising its proprietary EarlyCDT® platform technology. Oncimmune has pioneered the development of autoantibody tests that can detect cancer up to four years earlier than other methods and can be applied to a very wide range of solid tumour types. The Company's first product, EarlyCDT®-Lung, was launched in 2012, as a CLIA test in the USA and since then over 156,000 commercial tests have been sold. EarlyCDT®-Lung is available through physicians in the US and also privately in the UK, Europe & Asia. EarlyCDT®-Lung is being used in the largest ever randomised trial for the early detection of lung cancer using biomarkers, the National Health Service (NHS) Scotland ECLS study of 12,210 high-risk smokers. EarlyCDT®-Liver launched in May 2018 and further tests are in development.

Oncimmune, headquartered in Nottingham, United Kingdom with testing facilities in the US, joined AIM in May 2016 under the ticker ONC.L. For more information, visit www.oncimmune.com